E25Bio, a Cambridge, Mass.-based developer of rapid diagnostic tests, raised $2m in financing.
Khosla Ventures made the investment.
The new funding will go towards research and development, clinical studies, and scaling the company’s launch for diagnostic tests upon receiving EUA approval.
Founded in 2018 and led by Dr. Bobby Brooke Herrera, CEO, E25Bio develops technology for rapid diagnosis of dangerous infectious diseases such as dengue, zika, and now the novel coronavirus.
Based on technology developed by Dr. Irene Bosch and Dr. Lee Gehrke, the Hermann von Helmholtz Professor of Health Sciences and Technology at MIT, the company’s rapid diagnostic tests use nanoparticle technology to capture virus or viral proteins secreted into the human body. E25Bio is based out of The Engine at MIT.
FinSMEs
18/03/2020